Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Prepaid Assets: 2022-2025

Historic Prepaid Assets for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Sep 2025 value amounting to $1.2 million.

  • Corvus Pharmaceuticals' Prepaid Assets rose 1.92% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year increase of 1.92%. This contributed to the annual value of $2.4 million for FY2024, which is 203.20% up from last year.
  • Latest data reveals that Corvus Pharmaceuticals reported Prepaid Assets of $1.2 million as of Q3 2025, which was down 4.97% from $1.3 million recorded in Q2 2025.
  • Corvus Pharmaceuticals' Prepaid Assets' 5-year high stood at $2.4 million during Q4 2024, with a 5-year trough of $655,000 in Q1 2023.
  • Moreover, its 3-year median value for Prepaid Assets was $977,000 (2024), whereas its average is $1.1 million.
  • As far as peak fluctuations go, Corvus Pharmaceuticals' Prepaid Assets plummeted by 50.08% in 2023, and later surged by 203.20% in 2024.
  • Corvus Pharmaceuticals' Prepaid Assets (Quarterly) stood at $773,000 in 2022, then increased by 1.03% to $781,000 in 2023, then surged by 203.20% to $2.4 million in 2024, then grew by 1.92% to $1.2 million in 2025.
  • Its Prepaid Assets stands at $1.2 million for Q3 2025, versus $1.3 million for Q2 2025 and $1.2 million for Q1 2025.